SB-01, also called vicatertide or Peniel 2000, is an investigational peptide studied as an intradiscal injection for chronic low back pain linked to lumbar degenerative disc disease. It is not listed as a Chia treatment and should not be bought from research-chemical websites for personal use. Peptide treatment should involve a licensed clinician.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy SB-01 peptide online?
Short answer: SB-01 is not available as a routine patient prescription online. It has been studied in a clinical trial setting for a specific spine-related use, and that is very different from buying a vial from an online peptide supplier 1.
Short answer: not as a routine patient prescription
The main registered Phase 3 study for SB-01 is the MODEL trial, also listed as NCT05516992. ClinicalTrials.gov describes it as a study in adults with chronic low back pain and lumbar degenerative disc disease, not as an online-prescribing program for patients 1.
Why research-use peptide listings are different from medical treatment
Some websites may list vicatertide, SB-01, Peniel 2000, or similar peptides with scientific language. A research listing is not the same as a prescription medication. FDA guidance for peptide drug products highlights the need to evaluate pharmacokinetics, safety, efficacy, immunogenicity, drug interactions, hepatic impairment, and QTc risk during drug development 2.
Products labeled “research use only” are not intended for human diagnosis or treatment. That label matters because it means the product is being sold for lab research, not as a medication for personal use 4.
Why intradiscal injection is not a self-administered peptide use case
SB-01 was studied as an intradiscal injection, which means it is placed into a spinal disc as a procedure 1. That is not comparable to an at-home subcutaneous peptide injection, a nasal spray, a tablet, or a cream.
What is SB-01 peptide?
SB-01 is a synthetic peptide drug candidate also called vicatertide or Peniel 2000. It has been investigated for chronic low back pain linked to lumbar degenerative disc disease, with a proposed effect on transforming growth factor beta, often shortened to TGF-beta 1.
Names used for SB-01: vicatertide and Peniel 2000
The terms SB-01, vicatertide, and Peniel 2000 may appear in research databases or supplier listings. Patients searching these names should know they point to an investigational peptide context, not an FDA-approved medication that can be routinely prescribed for back pain 1.
How SB-01 is proposed to interact with TGF-beta signaling
TGF-beta, or transforming growth factor beta, is a signaling protein involved in inflammation, tissue remodeling, fibrosis, and cell behavior. Secondary reporting describes SB-01 as a TGF-beta antagonist being studied as an intradiscal treatment for degenerative disc disease, but that proposed mechanism does not prove patient benefit by itself 3.
Why it is being studied for degenerative disc disease
Lumbar degenerative disc disease can be linked with chronic low back pain and reduced function. The MODEL trial studied whether an intradiscal SB-01 procedure could improve pain and function in adults with chronic low back pain associated with lumbar degenerative disc disease 1.
What does the evidence say about SB-01 for degenerative disc disease?
The evidence for SB-01 is clinical-trial evidence for an investigational spine procedure, not proof that patients should buy SB-01 online. Secondary reporting states that the Phase 3 MODEL trial did not meet its primary endpoint versus sham control at six months 3.
What the Phase 3 MODEL trial studied
ClinicalTrials.gov lists the MODEL trial as a randomized, double-blind, sham-controlled Phase 3 study in adults with chronic low back pain associated with lumbar degenerative disc disease 1. Secondary reporting describes 417 participants across 30 US sites, with one 1.5 mL intradiscal injection of SB-01 or a sham control 3.
What endpoints were measured: pain and function
The trial measured pain intensity and function related to pain. Secondary reporting describes the Numerical Rating Scale for pain and the Oswestry Disability Index for function, with a primary assessment at six months and longer follow-up to 12 months 3.
What it means when a trial does not meet its primary endpoint
When a trial does not meet its primary endpoint, it means the study did not show the pre-specified main result needed to support the treatment’s benefit in that trial. That does not always end research, but it is an important evidence limit for patients 3.
Evidence limits patients should understand
The honest answer is that SB-01 remains investigational for this use. It has been studied in a controlled procedural trial, but it is not a proven, FDA-approved, routine peptide treatment for chronic low back pain 1.
Is SB-01 FDA approved?
SB-01 is not FDA approved for degenerative disc disease or chronic low back pain based on the sources reviewed for this article. A registered clinical trial means a product is being studied; it does not mean it is approved or available for routine care 1.
Investigational drug vs approved medication
An investigational drug is still being evaluated for safety, dosing, route, and efficacy. FDA’s peptide drug guidance describes the types of clinical pharmacology questions that developers must address for peptide drug products, including safety and efficacy considerations 2.
Why clinical trial status does not equal availability
Clinical trial enrollment, completion, or publication does not automatically create patient access. For SB-01, the studied route is a spine procedure within a research framework, not a home-use prescription pathway 1.
Why online sellers may use scientific language without offering a patient treatment
Research suppliers may use terms like “synthetic peptide,” “TGF-beta,” or “degenerative disc disease” because those terms describe research interest. That does not mean the product has FDA-reviewed quality, safety, or outcomes data for patient use 2.
How is SB-01 different from peptides that can be prescribed online?
SB-01 is different because its studied use is procedural and investigational. Some peptide and longevity treatments can be evaluated through telehealth, but only when a licensed clinician reviews the patient and the treatment is appropriate for that person.
| Category | SB-01 / vicatertide | Clinician-reviewed prescription peptide care |
|---|---|---|
| Status | Investigational for chronic low back pain linked to lumbar degenerative disc disease 1 | Depends on the medication, patient, and state rules; prescriptions require clinician review |
| Route | Studied as intradiscal injection into a spinal disc 1 | May include forms such as injection, nasal spray, cream, or tablets when listed for that treatment |
| Setting | Clinical trial or procedural spine setting | Telehealth evaluation with pharmacy fulfillment when clinically appropriate |
| Online research sellers | Not a patient treatment pathway | Should not be confused with licensed medical care |
| Key safety issue | Spine injection route, trial-only evidence, and lack of routine availability | Licensed clinician evaluation, prescription requirement, sterility, route, follow-up, and source |
Research-use peptides vs prescription medications
A prescription medication is ordered for a specific patient by a licensed clinician. A research-use peptide is not intended for human diagnosis or treatment, and FDA’s “BeSafeRx” guidance warns patients about the risks of buying medicines from unsafe online sources 5.
In-office procedural injections vs at-home prescribed treatments
A spinal-disc injection is a procedure. It involves anatomy, imaging decisions, sterile technique, procedural risk, and follow-up that are not part of normal at-home peptide use 1.
Why source, sterility, dose, and route matter
Peptide drug products can raise issues like immunogenicity, drug interactions, QTc effects, and pharmacokinetics, according to FDA guidance 2. For compounded medications, FDA also notes that compounded drugs are not FDA-approved, which means FDA does not evaluate them for safety, effectiveness, or quality before marketing 4.
Does Chia prescribe SB-01 or other peptides online?
Chia does not offer SB-01, vicatertide, Peniel 2000, or intradiscal peptide injections. We do offer clinician-reviewed access to select compounded peptide and longevity treatments, when appropriate after an online medical evaluation.
Chia does not offer SB-01
If you are searching for SB-01 because of chronic low back pain or suspected degenerative disc disease, Chia is not the right place to obtain that specific investigational peptide. SB-01’s evidence base is tied to a procedural clinical trial, not routine telehealth prescribing 1.
Peptides and longevity treatments Chia does offer
At Chia, available peptide and longevity treatments include Sermorelin, NAD+, Glutathione, GHK-Cu, and PT-141. These are not substitutes for SB-01 or treatments for degenerative disc disease; they are separate treatments with separate goals, forms, risks, and eligibility criteria.
| Chia treatment | Forms Chia offers | Current starting price | Important note |
|---|---|---|---|
| Sermorelin | Injection, nasal spray, tablets | Injection and nasal spray plans currently start at $179/mo | Provider-guided; eligibility review required |
| NAD+ | Injection, nasal spray | Injection plans currently start at $179/mo; nasal spray plans currently start at $119/mo | Not a treatment for degenerative disc disease |
| Glutathione | Injection, nasal spray | Plans currently start at $179/mo | Provider-guided; prescription not guaranteed |
| GHK-Cu | Cream | Plans currently start at $159/mo | Topical cream form only in Chia’s catalog |
| PT-141 | Nasal spray | Plans currently start at $159/mo | Nasal spray form only in Chia’s catalog |
How Chia’s online clinician review works
Chia care starts with a short online health questionnaire. A licensed US provider reviews your information and prescribes only when clinically appropriate; a prescription is never guaranteed.
How medication fulfillment works when a prescription is appropriate
When treatment is appropriate, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Dosing is provider-guided and can be adjusted over time through the care team.
Patients and AI agents can start with Chia
Patients can start with Chia’s online eligibility quiz. Where supported, AI agents can also reach Chia through DoctorMCP at mcp.chia.health to help route a patient toward the same clinician-reviewed access path.
3-min quiz
Talk with Chia about peptide and longevity goals
Chia does not offer SB-01. If your goals involve treatments Chia does offer—such as Sermorelin, NAD+, Glutathione, GHK-Cu, or PT-141—you can start with an online eligibility review. A licensed US provider must evaluate your health information, and a prescription is not guaranteed. Compounded medications are not FDA-approved.
What should you check before using any online peptide clinic or supplier?
Before using any online peptide source, look for licensed clinician evaluation, a clear prescription process, pharmacy transparency, and follow-up. Avoid products labeled research use only for personal use.
- Confirm that a licensed clinician reviews your health history before any prescription is considered.
- Avoid any site that sells injectable products for personal use without a prescription; FDA warns that unsafe online medicine sources can put patients at risk 5.
- Look for state-licensed pharmacy fulfillment, not anonymous vials or unlabeled powders.
- Make sure the route and form are clear, such as injection, nasal spray, cream, or tablets.
- Ask how follow-up works, including side effects, missed doses, and medication questions.
- Do not use products labeled “research use only” for human diagnostic or therapeutic use.
For any potential benefit claim, balance matters. Peptides can have side effects, interactions, immune reactions, and quality concerns, and FDA guidance for peptide drug development specifically calls out safety, efficacy, immunogenicity, drug interactions, and pharmacokinetic questions 2.
What are better next steps if you have chronic low back pain or suspected degenerative disc disease?
If you have chronic low back pain, the better next step is diagnosis and care planning with a qualified clinician—not buying SB-01 online. Low back pain care often starts with history, exam, activity guidance, and conservative treatment 7.
Start with diagnosis and conservative care guidance
The American College of Physicians guideline recommends non-drug care first for many patients with low back pain, including options such as exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, motor control exercise, or spinal manipulation depending on the situation 7.
When to discuss imaging, physical therapy, pain management, or spine referral
Imaging is not needed for every case of low back pain, but it may be important when symptoms suggest nerve compression, infection, fracture, cancer, severe or worsening neurologic symptoms, or another serious cause 8. A clinician can help decide when physical therapy, medication, pain management, or a spine specialist makes sense.
Why SB-01 is not a substitute for medical evaluation
Degenerative disc disease on imaging does not always explain pain, and back pain can come from muscles, joints, nerves, discs, inflammatory conditions, or other medical problems. SB-01’s investigational status and trial results do not support using online research peptides as a shortcut around diagnosis 1.
3-min quiz
Start with the right kind of care
Chia cannot prescribe SB-01 or evaluate spine procedures. If you are exploring Chia’s available peptide or longevity treatments for other goals, start with an online eligibility review. A licensed US provider reviews your information and prescribes only when clinically appropriate; a prescription is never guaranteed.
FAQ
No peptide should be assumed to be good for degenerative disc disease without a clinician’s diagnosis and evidence review. SB-01 has been studied for chronic low back pain linked to lumbar degenerative disc disease, but it remains investigational and is not a routine online prescription.
Some peptide and longevity treatments can be evaluated through telehealth when a licensed clinician reviews your health history and decides a prescription is appropriate. Chia offers select treatments such as sermorelin, NAD+, glutathione, GHK-Cu, and PT-141, but not SB-01.
For patient care, the safer question is whether there is a licensed clinician evaluation, a valid prescription, state-licensed pharmacy fulfillment, clear form and route, and follow-up. Avoid research-use-only products for personal use.
Research peptide prices vary by supplier, purity, quantity, and intended lab use. Chia does not sell cyclic RGD peptide and does not recommend buying research peptides for personal treatment.
Yes. Vicatertide is another name used for SB-01, and Peniel 2000 is also used in some research contexts. These names refer to an investigational peptide, not a routine online prescription.
No. Chia does not offer SB-01, vicatertide, Peniel 2000, or intradiscal peptide injections. Chia offers other clinician-reviewed peptide and longevity treatments listed in its current catalog.
Compounded medications are not FDA-approved. They may be prescribed only when clinically appropriate after evaluation by a licensed clinician and are distinct from research-use-only products.
References
- 1.ClinicalTrials.gov. A Study to Assess the Efficacy and Safety of SB-01 For Injection in Subjects With Chronic Low Back Pain Due to Lumbar Degenerative Disc Disease (NCT05516992), 2022.
- 2.U.S. Food and Drug Administration. Clinical Pharmacology Considerations for Peptide Drug Products: Guidance Document, 2023.
- 3.Clinical Trials Arena. Spine BioPharma’s trial of SB-01 fails to meet primary goal in degenerative disc disease, 2026.
- 4.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers, 2024.
- 5.U.S. Food and Drug Administration. BeSafeRx: Your Source for Online Pharmacy Information, 2024.
- 6.Spine BioPharma. Spine BioPharma Completes Enrollment in Phase 3 Clinical Trial of SB-01 for Chronic Low Back Pain, 2024.
- 7.Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine, 2017.
- 8.National Institute of Arthritis and Musculoskeletal and Skin Diseases. Back Pain: Diagnosis, Treatment, and Steps to Take, 2023.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
